Purchase of MALDI Biotyper

The Food and Drug Administration is seeking to replace the nonfunctional Bruker Biotyper system in its SA laboratory with a new MALDI-TOF MS instrument to enable rapid and accurate bacterial identification, including critical pathogens such as Clostridium botulinum and its neurotoxin. This procurement is essential for maintaining the laboratory’s capacity for microbial analysis, ensuring timely detection and characterization of hazardous organisms relevant to public health and safety. The system will support high-throughput diagnostics and enhance the agency’s ability to respond to potential biothreats and foodborne illness outbreaks. This opportunity is posted as a forecast under NAICS code 541990 and is managed by the FDA’s HFP Acquisition Liaison, with contact information provided for procurement inquiries. The contracting officer position remains to be determined, and no set-aside classification has been specified. The place of performance and detailed location information have not been provided, but the system will be deployed in the FDA’s SA laboratory. The posting date indicates this is a future procurement anticipated in 2026, allowing vendors to prepare proposals and engage with the agency prior to formal solicitation.